Company news

Imugene Ltd news in 2026

Imugene Ltd's news releases, calls and decks from 2026, newest first.

View company

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Further Responses in azer-cel Phase 1b Trial

October 18, 2026

Further Responses in azer-cel Phase 1b Trial

October 18, 2026

azer-cel BTKi Cohort Reports new Complete & Partial Response

October 4, 2026

Third response in concurrent BTKi Cohort of azer-cel Trial

July 26, 2026

$11.1 Million Placement Completed to Advance azer-cel

July 6, 2026

New Complete Response in the Concurrent BTKi azer-cel Cohort

June 30, 2026

First Complete Response in Concurrent BTKi azer-cel Cohort

June 29, 2026

Azer-cel Granted FDA Fast Track Designation for CLL and MZL

June 8, 2026

First Patient in BTKi Combination Cohort of azer-cel study

May 27, 2026

Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract

May 21, 2026

Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU)

May 20, 2026

Prospectus

March 17, 2026

$20M placement and SPP, convertible notes amended

March 11, 2026

100% and 80% ORRs in Subset Indications in azer-cel study

March 9, 2026

Trading Halt

March 9, 2026

Half Yearly Report and Accounts

February 25, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 29, 2026

Decks in 2026